Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 41 Carcinoma, Non-Small-Cell Lung 31 Triple Negative Breast Neoplasms 23 Nasopharyngeal Carcinoma 23 Stomach Neoplasms 22 Esophageal Neoplasms 20 Esophageal Squamous Cell Carcinoma 19 Breast Neoplasms 18 Squamous Cell Carcinoma of Head and Neck 14 Uterine Cervical Neoplasms 12 Colorectal Neoplasms 12 Sarcoma 10 Pancreatic Neoplasms 9 Lung Neoplasms 9 Recurrence 7 Neoplasm Metastasis 7 Melanoma 6 Liver Neoplasms 6 Hodgkin Disease 6 Cholangiocarcinoma 6 Biliary Tract Neoplasms 5 Advanced Gastric Cancer 5 Small Cell Lung Carcinoma 4 Osteosarcoma 4 Neoplasms 4 Locally Advanced Gastric Cancer 4 Advanced Solid Tumor 4 Solid Tumor 3 Respiratory Tract Diseases 3 Rectal Neoplasms 3

Interventions

toripalimab 1 camrelizumab 1 Radiotherapy 1 Nivolumab 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Tumors × camrelizumab × Clear all

NCT05799183 2024-12-31

A SHR-1210 BE Study on Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡